Ready-made stem cell therapies for pets could be coming

In a significant development for veterinary medicine, San Diego-based startup Gallant has secured $18 million in funding aimed at introducing the first FDA-approved ready-to-use stem cell therapy for pets. If the therapy clears regulatory hurdles, it could revolutionize the way we address health issues in our beloved animals. Gallant, founded seven years ago, is initially focusing on a painful condition affecting cats known as Feline Chronic Gingivostomatitis (FCGS). The company anticipates that this innovative therapy could receive FDA approval as early as 2026. Preliminary studies have shown promising results, particularly with canine patients suffering from arthritis, where many experienced notable relief from pain and improved mobility, with benefits lasting up to two years. However, results have been less consistent for other conditions, such as kidney disease in cats, which Gallant also aims to address. What sets Gallant apart from existing stem cell therapies is its unique approach to convenience. Unlike traditional methods that necessitate harvesting cells from the patient or a compatible donor, Gallant's therapy utilizes ready-to-use stem cells sourced from donor animals, regardless of species compatibility. The potential of this innovation has captured the attention of investors. The latest funding round was spearheaded by Digitalis Ventures, with additional support from NovaQuest Capital Management, a firm that has previously invested in the first FDA-approved human stem cell therapy. Gallant has an intriguing history: its founder, Aaron Hirschhorn, previously sold DogVacay to Rover, its main competitor in the dog-sitting industry. Following Hirschhorn's passing in 2021, Linda Black took the helm as president and chief scientific officer, having played a pivotal role in the company since its inception. To date, Gallant has raised a total of $44 million from various investors, indicating strong confidence in its mission and potential impact on pet healthcare.